Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Memory Clinic, Skåne University Hospital, Malmö, Sweden.
Mov Disord. 2021 Mar;36(3):767-771. doi: 10.1002/mds.28370. Epub 2020 Dec 7.
Alzheimer's disease co-pathology is common in dementia with Lewy bodies and Parkinson's disease with dementia (Lewy body disease) and can reliably be detected with positron emission tomography (PET) or cerebrospinal fluid (CSF) biomarkers. Recently developed blood biomarkers are more accessible and less expensive alternatives.
To investigate if plasma phospho-tau217 and phospho-tau181 can detect Alzheimer's pathology in Lewy body disease with dementia.
In this cross-sectional study we investigated plasma phospho-tau217 and phospho-tau181 in 35 patients with Lewy body disease with dementia. Patients underwent tau-PET imaging ( F-RO948).
Plasma phospho-tau217 correlated with plasma phospho-tau181, CSF phospho-tau217 (r = 0.68, P < 0.001), and negatively with CSF β-amyloid (r = -0.52, P = 0.001). Plasma phospho-tau217 and phospho-tau181 correlated with tau-PET signal in the temporal cortex (r > 0.56, P < 0.001) and predicted abnormal tau-PET status and β-amyloid status (area under the curve > 0.78 and > 0.81, respectively).
Plasma phospho-tau might be a useful marker for Alzheimer's co-pathology in Lewy body disease with dementia. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
阿尔茨海默病共病在路易体痴呆和帕金森病伴痴呆（路易体病）中很常见，可以通过正电子发射断层扫描（PET）或脑脊液（CSF）生物标志物可靠地检测到。最近开发的血液生物标志物是更易获得且更经济的替代方法。
研究血浆磷酸化tau217 和磷酸化tau181 是否可以检测路易体病伴痴呆中的阿尔茨海默病病理。
在这项横断面研究中，我们调查了 35 例路易体病伴痴呆患者的血浆磷酸化 tau217 和磷酸化 tau181。患者接受了 tau-PET 成像（F-RO948）。
血浆磷酸化 tau217 与血浆磷酸化 tau181、CSF 磷酸化 tau217（r = 0.68，P < 0.001）相关，与 CSF β-淀粉样蛋白呈负相关（r = -0.52，P = 0.001）。血浆磷酸化 tau217 和磷酸化 tau181 与颞叶皮质的 tau-PET 信号相关（r > 0.56，P < 0.001），并预测异常 tau-PET 状态和 β-淀粉样蛋白状态（曲线下面积 > 0.78 和 > 0.81，分别）。
血浆磷酸化 tau 可能是路易体病伴痴呆中阿尔茨海默病共病的有用标志物。
